Cardiovascular Research Advance Access originally published online on April 5, 2008
Cardiovascular Research 2008 79(2):238-248; doi:10.1093/cvr/cvn093
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Insulin signalling in the heart
1 CARD Unit, Division of Cardiology, Université catholique de Louvain, 55, Avenue Hippocrate, CARD5550, 1200 Brussels, Belgium
2 Hormone and Metabolic Research Unit, de Duve Institute, Université catholique de Louvain, Brussels, Belgium
* Corresponding author. Tel: +32 2 764 55 52; fax: +32 2 764 55 36. E-mail address: luc.bertrand{at}uclouvain.be
The main role of insulin in the heart under physiological conditions is obviously the regulation of substrate utilization. Indeed, insulin promotes glucose uptake and its utilization via glycolysis. In addition, insulin participates in the regulation of long-chain fatty acid uptake, protein synthesis, and vascular tonicity. Significant advancements have been made over the last 20 years in the understanding of the signal transduction elements involved in these insulin effects. Among these molecular mechanisms, the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway is thought to play a crucial role. Under pathological conditions, such as type-2 diabetes, myocardial ischaemia, and cardiac hypertrophy, insulin signal transduction pathways and action are clearly modified. These molecular signalling alterations are often linked to atypical crosstalks with other signal transduction pathways. On the other hand, pharmacological modifications of parallel and interdependent signalling components, such as the AMP-activated protein kinase pathway, are now considered to be a good therapeutic approach to treat insulin-signalling defects such as insulin resistance and type-2 diabetes. In this review, we will focus on the description of the molecular signalling elements involved in insulin action in the heart and vasculature under these different physiological, pathological, and therapeutical conditions.
KEYWORDS Energy metabolism; PKB/Akt; Ischaemia; Protein synthesis; Insulin resistance; AMPK
Time for primary review: 21 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
H.-Y. Liu, J. Han, S. Y. Cao, T. Hong, D. Zhuo, J. Shi, Z. Liu, and W. Cao Hepatic Autophagy Is Suppressed in the Presence of Insulin Resistance and Hyperinsulinemia: INHIBITION OF FoxO1-DEPENDENT EXPRESSION OF KEY AUTOPHAGY GENES BY INSULIN J. Biol. Chem., November 6, 2009; 284(45): 31484 - 31492. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-S. Tsou, V. Addanki, J. A. Haas, N. A. Page, and H.-L. Fung Role of Glutaredoxin-Mediated Protein S-Glutathionylation in Cellular Nitroglycerin Tolerance J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 649 - 656. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Youn, T. Wang, and H. Cai An Ezrin/Calpain/PI3K/AMPK/eNOSs1179 Signaling Cascade Mediating VEGF-Dependent Endothelial Nitric Oxide Production Circ. Res., January 2, 2009; 104(1): 50 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Vaughan-Jones and P. Swietach Pushing and Pulling the Cardiac Sodium/Hydrogen Exchanger Circ. Res., October 10, 2008; 103(8): 773 - 775. [Full Text] [PDF] |
||||
![]() |
G. D. Lopaschuk and D. P. Kelly Signalling in cardiac metabolism Cardiovasc Res, July 15, 2008; 79(2): 205 - 207. [Full Text] [PDF] |
||||



